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Abstract
Studies have shown that women diagnosed with herpes simplex virus-2 (HSV-2) have a higher risk 
for bacterial vaginosis (BV) infection. We investigated the presence of HSV-2 infections as a risk 
factor for incident BV infections in high risk, Human immunodeficiency virus (HIV) uninfected 
women enrolled in a HIV prevention trial in Durban, South Africa. The Vaginal and Oral 
Interventions to Control the Epidemic trial was a multicentre, double blinded, randomized 
controlled trial which was designed to estimate the effectiveness of daily treatment with vaginal 
tenofovir gel, oral tenofovir disoproxil fumarate and oral Truvada in preventing HIV-1 infection in 
women. Women provided samples for the diagnosis of HSV-2 and BV. The presence of HSV-2 
antibodies was detected using HerpeSelect™ ELISA IgG. Bacterial vaginosis was diagnosed using 
the Nugent scoring system. To assess the risk of BV incidence, modelled as a time-dependent 
variable, we used the Andersen-Gill model with robust variance estimation and Efron methods for 
ties. Overall, 2750 women were enrolled in the VOICE trial at our study sites. Women who had a 
HSV-2 infection at enrolment were shown to be at increased risk for incident BV infections 
(adjusted hazard ratio 1.17, 95% CI 1.08, 1.27, p ≤ 0.001). In addition, being of a young age, being 
unmarried and having a partner that has other partners were significantly associated with 
subsequent BV infection. Our findings therefore advocate the need for strengthening STI 
prevention efforts among women in high burden STI settings.
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Introduction
Herpes simplex virus-2 (HSV-2) is one of the most prevalent viral sexually transmitted 
infections (STIs) globally, with rates as high as 78% in women [1, 2]. According to the 
World Health Organization (WHO), 536 million people aged 15–49 are infected with 
HSV-2, the causative agent of genital herpes [3]. In addition, approximately 23.6 million 
people in this age group become newly infected with HSV-2 each year [3]. Women in Sub-
Saharan Africa have been shown to harbour the highest number of HSV-2 infections (i.e., 
70%) [3]. In South Africa, the prevalence of HSV-2 infection is reported to be 40–70% [4, 
5]. Bacterial vaginosis (BV) represents the main cause of abnormal vaginal discharge in 
women of reproductive age [6], and has been linked to considerable gynecologic and 
obstetric morbidity such as preterm delivery, pelvic inflammatory disease (PID) and upper 
genital tract infections [7]. The prevalence of BV has been reported to be as high as 51% 
among African women [8].
Many epidemiological studies have found a strong association between HSV-2 infection and 
Human Immunodeficiency Virus (HIV) infection [9]. In a more recent study by Abbai et al. 
[5], the prevalence of HSV-2 and HIV co-infection was reported to be 41% in South African 
women. Additionally, HSV-2 infection may also enhance host susceptibility to other STIs as 
well as lead to alterations in vaginal bacterial microbiota [10].
Bacterial vaginosis (BV) has also been found to be a significant risk factor for HIV-1 
acquisition [7]. It has also been suggested that BV may be a sexually associated condition 
since many studies have shown that BV positive individuals share similar risk factors with 
that of STI infected individuals [11].
According to Nagot et al. [12] HSV-2 infected women have a higher prevalence of BV when 
compared to uninfected women. A study by Kaul et al. [13] showed that women with 
prevalent HSV-2 infection have a higher incidence of BV compared to HSV-2 uninfected 
women. However, the above-mentioned studies were conducted using a targeted population, 
a cohort of sex workers, therefore the data derived from these studies are not applicable to 
the general population. In this study, we will determine the association between prevalent 
HSV-2 infections with the risk of incident BV infections in a large cohort of HIV uninfected 
women that had enrolled to participate in a HIV prevention trial in Durban, South Africa.
Methods
Study Sites and Population
This study was performed as a secondary analysis of the recently completed Vaginal and 
Oral Interventions to Control the Epidemic (VOICE) trial (Clinicaltrials.gov # 
NCT00705679). The VOICE trial was a multicentre, double blinded, randomized controlled 
trial which was designed to estimate the effectiveness of daily treatment with vaginal 
tenofovir (TVF) gel, as compared with placebo gel, and of oral tenofovir disoproxil fumarate 
(TDF) and oral Truvada (TDF-FTC), as compared with oral placebo, in preventing sexually 
acquired HIV-1 infection in women and to assess the safety profiles of each of the active 
treatments. The products tested were not shown to protect against HIV-1 infection [14]. The 
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trial was conducted from September 2009 through August 2012, at 15 sites in South Africa, 
Uganda and Zimbabwe. This study is based on the data collected from the 7 South African 
Medical Research Council clinical research sites (CRSs) in Durban, South Africa.
Participants were recruited from a variety of sources such as primary healthcare clinics, and 
family planning clinics, as well as various community-based locations. Participants were 
also referred to the study by peer educators [15], health and social service providers serving 
the target study population. Briefly, the inclusion criteria were women aged 18–45 years 
who were HIV negative, neither pregnant nor breast-feeding and who reported recent vaginal 
intercourse, were using effective contraception, and had normal renal, hematologic, and 
hepatic function [14]. The study protocol and informed consent forms were approved by 
local Institutional Review Boards/Ethics Committees (IRBs/ECs) prior to use. Written 
informed consent was obtained from all study participants.
Study Procedures
A detailed description of the study procedures are provided elsewhere [14]. Briefly, during 
study interviews, information on demographics, medical and menstrual history and sexual 
behaviour was obtained from enrolled women. This information was collected by 
interviewer administered questionnaires and audio computer-assisted self-interview 
(ACASI). The data recorded was based on self-report. Clinical procedures were conducted at 
screening, enrolment and during study follow-up visits. Participants underwent both physical 
and pelvic examinations. Samples were collected for the diagnosis of HSV-2, syphilis, 
Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, and BV infections. 
Ecto- and endocervical cells were also collected for Papanicolaou (Pap) smear analysis. 
Women were provided with HIV counselling and testing, ongoing HIV/STI risk reduction 
counselling, condoms, and treatment of STIs and reproductive tract infections (RTIs) such as 
BV and candida. Women were also advised to use a reliable method of contraception during 
the study and several contraception methods were available at the research site clinics. 
Participants were followed up monthly for a maximum of 36 months, with a minimum 
follow-up period of 12 months for those enrolled last.
Laboratory Procedures
Testing for HIV was conducted at every monthly visit, whereas testing for STIs and RTIs 
were conducted at baseline, annually, at study end and when clinically indicated. Two HIV 
rapid tests were conducted on whole blood samples collected by venipuncture by use of the 
Determine HIV-1/2 (Abbott Laboratories, Japan) and Unigold™ Recombigen® HIV. The 
presence of HSV-2 antibodies was detected using HerpeSelect™ ELISA IgG (Focus 
Technologies, Cypress, CA, USA) with a cut-off value of 3.5. Blood samples were used to 
diagnose syphilis using the rapid plasma reagin [RPR] and Treponema pallidum 
haemagglutinin [TPHA], Randox Laboratories, Crumlin, UK) tests. Urine specimens were 
collected for detection of N. gonorrhoeae, and C. trachomatis infections by strand 
displacement amplification using the BDProbeTec™ ET SDA Assay (Becton–Dickinson 
Microbiology Systems, USA). T. vaginalis testing was done using the Genzyme Rapid 
Trichomonas test with vaginal swabs.
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Measures
Outcome—The outcome of interest in this analysis was incidence of BV measured using 
the Nugent scoring system [16]. Scores of 0–3 were considered as negative, 4–6 
intermediate and 7–10 as positive BV status. The following quality control checks were in 
place for the Nugent scoring: in-house reproducibility checks (100%) were conducted by 
laboratory staff trained on reading BV slides. In addition, the slides and scores were assessed 
by an external laboratory which confirmed the scores read by the in-house laboratory. 
Women were tested for BV at the screening visit. If they tested BV positive they had a 56-
day window to receive treatment and be BV symptom free before enrolment. After 
enrolment the gram stain test was repeated at semi-annual, annual and product use end visit 
(PUEV). Woman-years of observation for incidence rate calculations were determined from 
enrolment date to date of gram stain testing. Being infected with BV was a recurrent event 
and a special statistical technique—Anderson-Gill Models—was used to account for this.
Predictor—Testing for HSV-2 infection was conducted at the study end on enrollment and 
PUEV plasma archive specimens. We used HSV-2 at enrolment as a predictor variable for 
BV infection in women who were BV negative at enrolment. Herpes simplex virus type 2 
was considered as negative for HerpeSelect EIA < 0.90, equivocal 0.90–1.89 and positive ≥ 
1.1. This was later dichotomized as negative (< 1.1) and positive (≥ 1.1).
Confounders—Informed by the literature [12, 13, 17, 18] we controlled for the following 
factors at enrolment confounding the association between HSV-2 status and incidence of 
BV: age (< 25, 25–34, ≥ 35), marital status (married vs not married), vaginal sex in last 4 
weeks (yes/no), coital frequency or number of sex acts in last 7 days, condom use in sex acts 
last 7 days (yes/no), type of condom used (male, female, none), circumcision of partner, 
partner having other partners and being diagnosed with a sexually transmitted infection 
(syphilis, N. gonorrhoeae, C. trachomatis and T. vaginalis).
Statistical Analysis
Differences in categorical variables by HSV-2 status (Table 1) and BV status at screening 
visit (Table 2) were analysed using Chi squared tests. We used the Andersen-Gill (A-G) 
model with robust variance estimation and Efron methods for ties [19] to assess the risk of 
BV incidence, modelled as a time-dependent variable. The risk of BV acquisition was 
conditioned on HSV-2 status at enrolment and adjusted for socio-demographic variables 
(age, marital status, partner having other partners, circumcision of partner), behavioural 
factors (sexual activity in the last 7 days, frequency of sex acts in last 4 weeks, condom use 
at last sex), abnormal pap smears, and STIs (N. gonorrhoeae, C. trachomatis, T. vaginalis, 
syphilis). Follow-up time was right-censored for women who HIV sero-converted. The 
proportionality assumption was assessed using schoenfeld, scaled schoenfeld and martingale 
residuals. There was no evidence of violation of the proportionality assumption. All models 
were confirmed as good fit using Cox-Snell residuals test of goodness.
Additional analyses were conducted using the commonly adopted approach of modelling 
time to first event. Results from the time to first event and from A–G models were very 
comparable; it changed neither the interpretation nor direction of association between 
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baseline HSV-2 prevalence and subsequent incident BV infections among the study 
participants. We thus focus here primarily on results from the more robust A–G models.
At the Durban sites of VOICE, 2750 women were enrolled, of whom one woman was 
excluded for being BV positive at enrolment, one participant had missing information on 
HSV-2 status at enrolment and 4 had no follow-up visits post-enrolment giving us a final 
sample size of 2744 for this analysis. All analyses were conducted using STATA version 
13.1 (College Station, TX: StataCorp LP).
Results
Characteristics of the Study Population by HSV-2 Status at Enrolment
Table 1 represents the baseline characteristics of the study population by HSV-2 status at 
enrolment. Overall, the prevalence rate for HSV-2 among the women at enrolment was 
57.5% (n = 1577/2744). The prevalence of HSV-2 significantly increased with age; it was 
highest (77.6%) in the oldest age women (≥ 35 years old) (p < 0.001). By marital status, 
58.2% of unmarried women compared to 47.3% of married women were HSV-2 positive at 
enrolment (p = 0.004). There were no significant differences in the prevalence of HSV-2 by 
coital activity in the last four weeks (p = 0.635), but HSV-2 status significantly varied (p = 
0.041) by coital frequency in the last seven days with the prevalence being highest (61.5%) 
among those with four or more sex acts in the last 7 days as compared to those women with 
few sex acts (p = 0.041). Women who had used condoms in last 7 days had the highest 
(59.6%) diagnosis of HSV-2, however, there was no significant difference in type of condom 
used. Diagnosis of HSV-2 at enrolment further significantly varied by whether a woman’s 
partner had other partners or partner was circumcised. Abnormal Pap smear findings, being 
diagnosed positive for N. gonorrheae or T. vaginalis infections were other factors 
significantly associated with HSV-2 positive status.
Prevalence and Associated Factors of BV at Screening Visit Prior to Enrolment
Table 2 represents the characteristics of the study population by BV status at screening visit 
prior to enrolment. Overall, the prevalence of BV positive women at screening was 40.7% (n 
= 1117/2744) and a further 16.3% were BV intermediate (n = 446/2744).
Within the group of women who were younger than 25 years of age, were unmarried and 
reported using condoms during their sex acts in the last 7 days, a larger percentage of 
women tested positive for BV. However, there was no significant association with prevalent 
BV infections, abnormal papsmear findings and prevalent STIs in the study population.
Factors Associated with Incidence of BV
Table 3 presents hazard ratios of the risk of incident BV infection over the study period by 
HSV-2 status of women at enrolment. Being HSV-2 positive at enrolment was significantly 
associated with incident BV infection in both unadjusted [hazard ratio (HR) 1.19, 95% 
confidence interval (CI) 1.10, 1.29, p < 0.001] and adjusted models (HR 1.17, 95% CI 1.08, 
1.27, p < 0.001). Among the socio-demographic factors we controlled for in the adjusted 
analyses: being 35 years or older (p = 0.08), not married (p < 0.001), partner not circumcised 
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and coital frequency in the last 7 days were all associated with increased likelihood of BV 
incidence. Whereas, being aged under 35 years (p = 0.01) and partner not having other 
partners (p = 0.002) was associated with significantly less likelihood of BV acquisition. In 
addition, syphilis (p < 0.001), C. trachomatis (p = 0.01) and T. vaginalis (p = 0.05) at 
enrolment were among the biological factors significantly associated with incident BV 
infection among women who were HSV-2 infected at enrolment.
Table 3 further shows that using the approach of time to first event (ignoring all subsequent 
incidents of BV), both the unadjusted (HR: 1.35, 95% CI: 1.21, 1.50, p < 0.001) and 
adjusted hazard ratios (HR 1.37, 95% CI 1.23, 1.53, p < 0.001) of the association between 
HSV-2 positivity at enrolment and subsequent incidence of BV infection were comparable 
albeit higher than in the A-G models.
Discussion
In this study, the prevalence of HSV-2 at enrolment was estimated at 57%. Our findings are 
similar to those published by Kenyon et al. [4] who reported a prevalence of 53.3% for 
HSV-2 in a cohort of young South African women. The possible biological mechanisms for 
the associated risk of BV infections in women that have prevalent HSV-2 infections is 
described by Cherpes et al. [17] It has been suggested that the presence of a genital herpes 
infection changes the physiological and immunological environment of the vagina. It has 
been hypothesized that the change in the vaginal environment facilitates the overgrowth of 
anaerobic bacteria which in turn decreases the survival of hydrogen peroxide producing 
lactobacilli. The decrease in vaginal lactobacilli increases the risk of BV [17].
Our study identified a significant association between prevalent HSV-2 infections and the 
acquisition of BV in line with other literature [12, 13, 17]. The smaller effect size we see in 
our analysis relative to what others found could have been influenced by requirements of the 
VOICE protocol which indicated that all women who screened BV positive had to be treated 
and be BV free within a 56-day window before enrolment. This excluded any individual 
who could have had a prevalent BV and HSV-2 infection at enrolment.
The limitations of our study are as follows. Firstly, our analysis was performed only with 
data from HIV negative women. It has been previously reported that immunodeficiency 
caused by HIV-1 infection increases the occurrence and severity of HSV-2 reactivations, 
thereby resulting in increased BV episodes in HIV-1-positive women [18]. For future 
studies, HIV-1 status will be an important consideration for describing the association 
between HSV-2 and future BV infections. As per the study protocol, diagnosis of HSV-2 
was only conducted at enrolment and at the end of study, therefore we were limited by the 
data to account for women who became HSV-2 infected during the trial. In addition, we are 
aware that confirming the results of the ELISA for HSV-2 with a Western blot would have 
provided a more accurate account on the actual number of HSV-2 infections, however, this 
was not a protocol requirement for the VOICE trial. However, in the VOICE trial HSV-2 
diagnosis was made using the second- generation HerpesSelect ELISA from Focus 
Diagnostics. Focus Diagnostics had released the second-generation HerpeSelect ELISA 
based on the poor performance of the first-generation HerpesSelect EIA. Mark et al. [20], 
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had found that samples that had discordant EIA and Western blot HSV-2 results using the 
first generation test, were no longer discordant when using the second-generation kit. Thus, 
it appears that the second-generation Focus ELISA is more specific than the first-generation 
test.
In this analysis we had data that could have multiple failure events per subject, for which 
statistical methods that are able to account for possible correlation within subjects and 
discontinuous risk intervals like the A–G models are appropriate [19, 21]. Others adopt more 
naïve approaches such as modeling time to first event or modelling the risk intervals as 
continous [22]. As a sensitivity analysis we did run time to first event models and found 
results thereof to be very comparable to what we got from the A–G models (Table 3). Hence 
our primary focus was on results from the A–G models as A–G models have been found to 
be reliable and efficient in modelling recurrent events [23, 24]. Our findings however are 
limited to the extent to which the recurrent events may or may not have been independent, 
which is a main assumption of the A–G models. Another limitation of this analysis relates to 
the timing of the BV assessments that were done at the screeining then at the semi-annual, 
annual and product use end visits. It is thus likely for some BV episodes to have been missed 
given the long intervals between BV assessments.
The strength of our study is that the data used for our analysis was collected from women 
who reside in a highly prevalent HSV-2 and BV setting. Our findings therefore advocate the 
need for strengthening STI prevention efforts among women in high burden STI settings.
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